These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16174833)

  • 1. Assessment of potential drug-drug interactions with a prescription claims database.
    Malone DC; Hutchins DS; Haupert H; Hansten P; Duncan B; Van Bergen RC; Solomon SL; Lipton RB
    Am J Health Syst Pharm; 2005 Oct; 62(19):1983-91. PubMed ID: 16174833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying high risk medications causing potential drug-drug interactions in outpatients: A prescription database study based on an online surveillance system.
    Toivo TM; Mikkola JA; Laine K; Airaksinen M
    Res Social Adm Pharm; 2016; 12(4):559-68. PubMed ID: 26459026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy.
    Gagne JJ; Maio V; Rabinowitz C
    J Clin Pharm Ther; 2008 Apr; 33(2):141-51. PubMed ID: 18315779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential drug-drug interactions within Veterans Affairs medical centers.
    Mahmood M; Malone DC; Skrepnek GH; Abarca J; Armstrong EP; Murphy JE; Grizzle AJ; Ko Y; Woosley RL
    Am J Health Syst Pharm; 2007 Jul; 64(14):1500-5. PubMed ID: 17617500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers.
    Ko Y; Malone DC; Skrepnek GH; Armstrong EP; Murphy JE; Abarca J; Rehfeld RA; Reel SJ; Woosley RL
    Drug Saf; 2008; 31(6):525-36. PubMed ID: 18484786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacist workload and pharmacy characteristics associated with the dispensing of potentially clinically important drug-drug interactions.
    Malone DC; Abarca J; Skrepnek GH; Murphy JE; Armstrong EP; Grizzle AJ; Rehfeld RA; Woosley RL
    Med Care; 2007 May; 45(5):456-62. PubMed ID: 17446832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of potentially serious drug-drug interactions among South African elderly private health sector patients using the Mimica Matanović/Vlahović-Palčevski protocol.
    van Heerden JA; Burger JR; Gerber JJ; Vlahović-Palčevski V
    Int J Pharm Pract; 2018 Apr; 26(2):156-164. PubMed ID: 28665037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the French healthcare insurance database to estimate the prevalence of exposure to potential drug-drug interactions.
    Souty C; Launay T; Steichen O; Conte C; Turbelin C; Sarazin M; Vilcu AM; Rossignol L; Blanchon T; Lapeyre-Mestre M; Hanslik T
    Eur J Clin Pharmacol; 2020 Dec; 76(12):1675-1682. PubMed ID: 32632714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically important potential drug-drug interactions in outpatient settings.
    Aparasu R; Baer R; Aparasu A
    Res Social Adm Pharm; 2007 Dec; 3(4):426-37. PubMed ID: 18082877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population.
    Peng CC; Glassman PA; Marks IR; Fowler C; Castiglione B; Good CB
    J Manag Care Pharm; 2003; 9(6):513-22. PubMed ID: 14664659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Countrywide prevalence of critical drug interactions in Hungarian outpatients: a retrospective analysis of pharmacy dispensing data.
    Somogyi-Végh A; Ludányi Z; Erdős Á; Botz L
    BMC Pharmacol Toxicol; 2019 May; 20(1):36. PubMed ID: 31151485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically relevant potential drug-drug interactions among outpatients: A nationwide database study.
    Jazbar J; Locatelli I; Horvat N; Kos M
    Res Social Adm Pharm; 2018 Jun; 14(6):572-580. PubMed ID: 28716467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coprescribing and codispensing of cisapride and contraindicated drugs.
    Jones JK; Fife D; Curkendall S; Goehring E; Guo JJ; Shannon M
    JAMA; 2001 Oct; 286(13):1607-9. PubMed ID: 11585484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validity of the days supply field in pharmacy administrative claims data for the identification of blister packaging of medications.
    Leong C; Sareen J; Leslie WD; Enns MW; Bolton J; Alessi-Severini S; Katz LY; Logsetty S; Snider C; Berry J; Prior HJ; Chateau D
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1540-1545. PubMed ID: 28856756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine.
    Ellis JJ; Sadosky AB; Ten Eyck LL; Mudumby P; Cappelleri JC; Ndehi L; Suehs BT; Parsons B
    BMC Health Serv Res; 2015 Apr; 15():159. PubMed ID: 25889173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential drug-drug interactions in prescriptions dispensed in community pharmacies in Greece.
    Chatsisvili A; Sapounidis I; Pavlidou G; Zoumpouridou E; Karakousis VA; Spanakis M; Teperikidis L; Niopas I
    Pharm World Sci; 2010 Apr; 32(2):187-93. PubMed ID: 20077137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of possible drug-drug interactions between antiretroviral agents in different age groups in a section of the private health care sector setting in South Africa.
    Katende-Kyenda NL; Lubbe MS; Serfontein JH; Truter I
    J Clin Pharm Ther; 2008 Aug; 33(4):393-400. PubMed ID: 18613857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring patient safety in ambulatory care: potential for identifying medical group drug-drug interaction rates using claims data.
    Solberg LI; Hurley JS; Roberts MH; Nelson WW; Frost FJ; Crain AL; Gunter MJ; Young LR
    Am J Manag Care; 2004 Nov; 10(11 Pt 1):753-9. PubMed ID: 15623265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of risk management plans: a case study of pemoline using pharmacy claims data.
    Morrato EH; Staffa JA
    Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):104-12. PubMed ID: 16821248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study.
    Ko Y; Tan SL; Chan A; Wong YP; Yong WP; Ng RC; Lim SW; Salim A
    Clin Ther; 2012 Aug; 34(8):1696-704. PubMed ID: 22795926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.